Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Chimeric Therapeutics Limited has announced an extension of the closing date for its non-renounceable entitlement offer to 22 April 2025. This extension provides shareholders with additional time to participate in the offer, potentially impacting the company’s capital structure and shareholder base. The offer includes the opportunity for eligible shareholders to apply for additional shares under a Top Up Facility, which could enhance shareholder value and support the company’s ongoing development of its cell therapy portfolio.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is a clinical stage cell therapy company based in Australia, specializing in innovative cancer treatments. The company focuses on developing and commercializing autologous CAR-T cell therapies and allogeneic NK cell therapies, with a diversified portfolio targeting various oncology diseases through four clinical stage programs.
Technical Sentiment Signal: Buy
Current Market Cap: A$11.34M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.